EvolutionaryScale is a public benefit company building AI models for biology, including protein design and structure prediction. Its mission is to improve understanding of biology for human health and society through open, safe research.
UpMarket does not offer EvolutionaryScale shares. This page covers EvolutionaryScale's history before the acquisition.
EvolutionaryScale was acquired by Chan Zuckerberg Biohub in November 2025 and no longer has shares of its own. UpMarket does not offer EvolutionaryScale shares. This page covers EvolutionaryScale's valuation and funding history before the acquisition.
EvolutionaryScale was acquired by Chan Zuckerberg Biohub in November 2025.
See how EvolutionaryScale's private-market valuation changed across funding rounds before the acquisition.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| Jun 2024 | Seed |
The New York biotech AI startup raised $142 million in seed funding in June 2024, one of the largest first-round financings in the sector. Its ESM3 platform is built to design novel proteins from sequence, structure, and function data across 2.78 billion natural proteins.
EvolutionaryScale says ESM3 was trained on 2.78 billion proteins using about 1 trillion teraflops of compute, giving it unusually large biological scale. The model can generate proteins such as esmGFP by simulating roughly 500 million years of evolution.
AWS announced a collaboration to give scientists access to EvolutionaryScale's ESM3 models for drug discovery and new protein creation. The open-source model is already on Amazon SageMaker and AWS HealthOmics, with broader availability planned through Amazon Bedrock.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. EvolutionaryScale was acquired by Chan Zuckerberg Biohub in November 2025 and no longer has shares of its own. UpMarket does not offer EvolutionaryScale shares.
EvolutionaryScale has no stock price of its own since its acquisition by Chan Zuckerberg Biohub. The prices shown on this page are historical private-market prices from before the acquisition.
No. EvolutionaryScale was acquired by Chan Zuckerberg Biohub and UpMarket does not offer EvolutionaryScale shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
EvolutionaryScale is no longer an independent company, so its shares are not available to buy. This page is kept for its historical funding and valuation data. UpMarket does not offer EvolutionaryScale shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
EvolutionaryScale was acquired by Chan Zuckerberg Biohub in November 2025. What former shareholders received, cash or shares of the buyer, was set by the terms of the acquisition.
UpMarket does not offer EvolutionaryScale shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
EvolutionaryScale's last valuation was set by its acquisition by Chan Zuckerberg Biohub. The figures on this page show its valuation history before the acquisition.
EvolutionaryScale builds AI models for biology and protein design, with a $1.21 billion UpMarket valuation estimate after its $142 million seed round to scale ESM3 and expand biological discovery. EvolutionaryScale is now part of Chan Zuckerberg Biohub, and UpMarket does not offer its shares.